SOL-GEL TECHN. IS-10 (4SG) - Net Assets
Based on the latest financial reports, SOL-GEL TECHN. IS-10 (4SG) has net assets worth €22.81 Million EUR (≈ $26.67 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€29.92 Million ≈ $34.98 Million USD) and total liabilities (€7.11 Million ≈ $8.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SOL-GEL TECHN. IS-10 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €22.81 Million |
| % of Total Assets | 76.25% |
| Annual Growth Rate | -19.97% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.69 |
SOL-GEL TECHN. IS-10 - Net Assets Trend (2021–2025)
This chart illustrates how SOL-GEL TECHN. IS-10's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of SOL-GEL TECHN. IS-10 to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for SOL-GEL TECHN. IS-10 (2021–2025)
The table below shows the annual net assets of SOL-GEL TECHN. IS-10 from 2021 to 2025. For live valuation and market cap data, see 4SG company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €22.81 Million ≈ $26.67 Million |
-20.93% |
| 2024-12-31 | €28.85 Million ≈ $33.73 Million |
-25.34% |
| 2023-12-31 | €38.64 Million ≈ $45.18 Million |
-8.45% |
| 2022-12-31 | €42.21 Million ≈ $49.35 Million |
-24.07% |
| 2021-12-31 | €55.59 Million ≈ $65.00 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SOL-GEL TECHN. IS-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5886800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €259.82 Million | 1139.02% |
| Total Equity | €22.81 Million | 100.00% |
SOL-GEL TECHN. IS-10 Competitors by Market Cap
The table below lists competitors of SOL-GEL TECHN. IS-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TON Strategy Co
NASDAQ:TONX
|
$188.25 Million |
|
Onewater Marine
NASDAQ:ONEW
|
$188.28 Million |
|
Gulf Island Fabrication Inc
NASDAQ:GIFI
|
$188.30 Million |
|
Saniona AB
ST:SANION
|
$188.35 Million |
|
SaltX Technology Holding AB
ST:SALT-B
|
$188.19 Million |
|
Central Industrial Corp
KLSE:8052
|
$188.15 Million |
|
BIDV Insurance Corp
VN:BIC
|
$188.10 Million |
|
GTM Holdings Corp
TW:1437
|
$187.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SOL-GEL TECHN. IS-10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,850,000 to 22,811,000, a change of -6,039,000 (-20.9%).
- Net loss of 6,127,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.13 Million | -26.86% |
| Other Changes | €88.00K | +0.39% |
| Total Change | €- | -20.93% |
Book Value vs Market Value Analysis
This analysis compares SOL-GEL TECHN. IS-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.51x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.56x to 7.51x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €24.04 | €61.50 | x |
| 2022-12-31 | €18.25 | €61.50 | x |
| 2023-12-31 | €13.87 | €61.50 | x |
| 2024-12-31 | €10.36 | €61.50 | x |
| 2025-12-31 | €8.19 | €61.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SOL-GEL TECHN. IS-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -26.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.60%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.31x
- Recent ROE (-26.86%) is above the historical average (-32.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 5.79% | 10.30% | 0.45x | 1.24x | €-2.34 Million |
| 2022 | -35.35% | -384.32% | 0.08x | 1.10x | €-19.14 Million |
| 2023 | -70.48% | -1752.77% | 0.03x | 1.17x | €-31.10 Million |
| 2024 | -36.67% | -91.70% | 0.32x | 1.24x | €-13.46 Million |
| 2025 | -26.86% | -31.60% | 0.65x | 1.31x | €-8.41 Million |
Industry Comparison
This section compares SOL-GEL TECHN. IS-10's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,435,678,106
- Average return on equity (ROE) among peers: -30.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SOL-GEL TECHN. IS-10 (4SG) | €22.81 Million | 5.79% | 0.31x | $188.23 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $179.82 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.05 Billion | -15.51% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.10 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.60 Million | -113.13% | 0.23x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $715.50 Million | -24.53% | 0.64x | $1.82 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $20.05 Billion |
About SOL-GEL TECHN. IS-10
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more